FINDINGS:
Comparison: 2023-09-15.
Lungs: No focal consolidation or suspicious pulmonary nodules. No pneumothorax. Post-treatment change: ground-glass opacities within field.
Mediastinum: Enlarged paratracheal lymph node, short axis 12 mm. Cardiomediastinal contours within normal limits.
Pleura/Pleural spaces: No pleural effusion or pleural thickening.
Great vessels/Aorta: No thoracic aortic aneurysm or dissection.
Liver: No focal hepatic lesions. Normal attenuation.
Spleen: Normal in size and attenuation. No focal splenic lesion.
Pancreas: 100 mm spiculated pancreatic mass in the tail of the pancreas (isoenhancing). Normal pancreatic contour and enhancement. No focal mass.
Adrenal glands: Adrenal glands are normal without nodules. no adrenal nodule.
Kidneys: No hydronephrosis. No enhancing renal mass.
GI tract/Bowel: No obstructive process. No focal bowel wall mass identified. diverticulosis. no bowel obstruction.
Mesentery/Omentum: No ascites. No omental caking. no peritoneal nodularity.
Mesenteric vessels (SMA/SMV): SMA/SMV are patent without thrombosis.
Urinary bladder: Unremarkable. no focal bladder wall thickening.
Reproductive organs: No adnexal mass. Uterus/prostate within expected size for age.
Lymph nodes: Enlarged celiac lymph node, short axis 27 mm. No pathologically enlarged lymph nodes by size criteria.
Bones/Osseous structures: No aggressive osseous lesion. No acute fracture. degenerative changes. no destructive osseous lesion.

IMPRESSION:
- Pancreas primary malignancy at tail of the pancreas measuring approximately 100 mm.
- Findings concerning for nodal involvement.
- No definite distant metastases identified.
- RECIST 1.1 Summary:
- Target lesions (n=2; ≤2 per organ rule applied).
  • T1: Primary — 79→100 mm (longest diameter).
  • T2: Lymph node — 23→27 mm (short axis).
- SLD baseline: 102 mm.
- SLD current: 127 mm (+24.5% change).
- New lesions: present (unequivocal).
- - RECIST 1.1 overall response category: PD.
